comparemela.com

Latest Breaking News On - Hansc lee - Page 1 : comparemela.com

Dr Lee on the Significance of Longer-Term Data for Linvoseltamab in R/R Multiple Myeloma

Hans C. Lee, MD, discusses the significance of longer-term data for linvoseltamab from the LINKER-MM1 study in relapsed/refractory multiple myeloma.

United statesHansc leeDepartment of lymphoma myelomaMyeloma clinical researchUniversity of texas md anderson cancer centerDivision of cancer medicineMultiple myeloma clinical researchCancer medicineCancer centerThe university of texas md anderson cancer centerOnclive tvMultiple myelomaPhase 2 linker mm1 study nct03761108Bcma cd3 directed bispecific antibody

Bristol Myers Squibb s First Disclosures and New Data at ASH 2023 Highlight Company s Leadership and Progress in Cell Therapy, Targeted Protein Degradation and Novel Approaches in Hematology -November 02, 2023 at 11:35 am EDT

First presentation of results from primary analysis of Phase 2 TRANSCEND FL study evaluating second-line treatment with Breyanzi® in relapsed or refractory follicular lymphoma demonstrate its.

United statesSan diegoSikander ailawadhiFrancesco passamontiLisocabtagene maraleucelGuillaume cartronRavi vijMaroof hasanMark kaplanRachid bazHemophagocytic lymphohistiocytosisDanny jeyarajuSheida hayatiSusan balSamit hirawatFranck morschhauser

Dr Lee on the Investigation of Linvoseltamab in Relapsed/Refractory Multiple Myeloma

Hans C. Lee, MD, discusses the investigation of the BCMA x CD3 bispecific antibody linvoseltamab in patients with relapsed/refractory multiple myeloma.

United statesHansc leeDivision of cancer medicineUniversity of texas md anderson cancer centerDepartment of lymphoma myelomaMyeloma clinical researchMultiple myeloma clinical researchCancer medicineCancer center

Linvoseltamab Shows High Response Rate, Manageable Toxicity for Pretreated Myeloma

The BCMA/CD3 bispecific linvoseltamab elicited an objective response rate of 71% at the recommended dose of 200 mg for patients with relapsed/refractory multiple myeloma.

United statesHansc leeUniversity of texas md anderson cancer centerAsco annual meeting

vimarsana © 2020. All Rights Reserved.